Geisinger Health System, a US-based medical services provider, has co-led the series A round for Cernostics, which helps diagnose cancer.
Alongside Geisinger’s corporate venturing unit in the round were venture capital firms Novitas Capital and the Pittsburgh Life Science Greenhouse.
Lansing Taylor, chief executive of Cellumen and chairman of Cernostics, said: "Cernostics was founded as a spin-off of Cellumen in 2008 to apply predictive science to tissue-based diagnostics using panels of fluorescence-labeled biomarkers and informatics. We are pleased to join forces with Geisinger Health System, Novitas Capital and Pittsburgh Life Sciences Greenhouse."
Geisinger will partner with Cernostics to develop diagnostic technologies to detect subtle differences in the cellular and molecular makeup of patient tissue samples and identify patients who are most likely to be receptive to specific cancer treatments.
Mike Hoerres, chief executive of Cernostics and a principal at Geisinger Ventures, said: "This unique combination of Cernostics’ technology and key Geisinger assets will lead to a wave of innovation in cancer pathology and diagnostics that supports Geisinger’s vision for personalized healthcare."